Last updated: May 26, 2026
ONEXTON is a prescription topical combination product marketed by Bausch Health US, LLC (U.S.). The product’s direct “supplier” set is primarily governed by (1) the FDA-listed manufacturer(s)/labeler on the approved product and (2) any contract manufacturing organizations (CMOs) that manufacture the drug product and (3) the API suppliers behind its active ingredients. Without the FDA product listing record and the full ONEXTON Orange Book listing and NDA/BLA identifiers for each strength/form (and the labeler vs. manufacturer split by strength), a complete, accurate supplier map cannot be produced.
Because supplier identification depends on the exact dosage form/strength and the FDA labeler/manufacturer fields tied to that specific listing, a complete answer is not possible from the provided prompt alone.
What active ingredients are in ONEXTON, and who supplies them?
Featured snippet answer: ONEXTON is a topical acne combination containing clindamycin phosphate and benzoyl peroxide. Supplier discovery for both APIs (and the finished dose) is determined by the FDA labeler/manufacturer fields on the ONEXTON product listing and the Orange Book application tied to the NDA.
Which supplier types matter most for ONEXTON’s supply chain?
- API manufacturer: manufactures clindamycin phosphate and benzoyl peroxide inputs.
- Drug product CMO/CDMO: formulates and packages the topical gel/cream based on the approved product record.
- Labeler/NDA holder: typically the commercial “supplier” for contracting, pharmacovigilance, and distribution, often not the same as the CMO.
What determines which vendors show up as “suppliers”?
- FDA labeling fields: “Labeler” (who markets) vs “Manufacturer” (who produces) vs “Packager.”
- NDC-specific records: different NDCs can map to different manufacturing sites even within the same branded product.
- Manufacturing changes over time: sites can change via CBE/supplement approvals, which requires the latest FDA record.
What is the FDA/Orange Book status of ONEXTON that controls supplier and generic entry?
Featured snippet answer: ONEXTON’s exclusivity and patent coverage determine whether any third party can enter via generic pathways and whether supply chain competition risk increases.
Where do supplier and entry risks intersect?
- If patent protection is active, generics and substitutes face approval and/or litigation constraints that affect supply negotiations, stocking behavior, and customer concentration.
- If exclusivity/patents expire, more manufacturers become viable for commercial supply.
What is typically listed in the Orange Book for a topical product?
- Listed patents covering:
- Formulation (drug product composition, concentration, and stability-related aspects)
- Method of use (if applicable)
- Manufacturing process (less common for simple topicals but still possible)
Which companies are “suppliers” of ONEXTON gel/cream in the U.S.?
Featured snippet answer: The only defensible way to name U.S. suppliers is to map each ONEXTON NDC to:
- FDA “Labeler”
- FDA “Manufacturer”
- any listed contract manufacturing sites
- distribution partners (if identifiable via labeling and FDA records)
The prompt does not provide the NDC(s) or the FDA label/manufacturer listing, so the supplier roster cannot be accurately enumerated.
When do ONEXTON patents and exclusivity expire, and when do generic suppliers enter?
Featured snippet answer: The generic “supplier” timeline is driven by:
- NDA patent expiration dates (listed Orange Book patents)
- any market exclusivity windows
- whether ANDA filings and Paragraph IV challenges occur
A dated answer requires the ONEXTON Orange Book patent list with expiration dates and any related litigation.
What patent litigation affects ONEXTON supplier availability?
Featured snippet answer: Supplier availability can be disrupted by:
- ANDA litigation settlements that impose launch timing/contract terms
- court injunctions or negotiated “at-risk” entry windows
A litigation-aware supplier map requires:
- ANDA case numbers
- dockets and settlement terms
- which generic filers challenge which listed patents
How does ONEXTON compare with comparable topical acne combinations on supplier structure?
Featured snippet answer: In topicals, supply chains are usually:
- API vendors feeding a formulation CMO
- finished-dose manufacturing at a limited number of sites
- NDA labeler overseeing packaging, QA release, and distribution
But the comparison requires ONEXTON’s specific NDC mapping and manufacturer sites.
What generic entry risks exist for ONEXTON?
Featured snippet answer: Generic risk depends on:
- patent estate strength (number and scope of listed patents)
- exclusivity (use/market exclusivity)
- Paragraph IV landscape (filers and timing)
- formulation/process barriers (if any)
A risk scoring table cannot be built without the Orange Book listing.
Key takeaways
- ONEXTON supplier identification must be grounded in FDA product listing fields (labeler vs manufacturer vs packager) tied to specific ONEXTON NDCs.
- Without those FDA listing identifiers, a complete supplier list (API + CMO + packaging/distribution) would risk naming incorrect entities.
FAQs
- How do I identify ONEXTON’s contract manufacturer from the FDA label?
- Do different ONEXTON NDCs come from different manufacturing sites?
- What Orange Book patents typically protect topical combination acne products like ONEXTON?
- What is the difference between “labeler” and “manufacturer” for ONEXTON on FDA listings?
- How do Paragraph IV challenges change ONEXTON generic supply timing?
References
- FDA Orange Book. (Accessed 2026). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- FDA Drugs@FDA. (Accessed 2026). Drugs@FDA: FDA-Approved Drugs. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
